CA3133204A1 - Drug and method for treating or preventing diabetes complications using same drug - Google Patents

Drug and method for treating or preventing diabetes complications using same drug

Info

Publication number
CA3133204A1
CA3133204A1 CA3133204A CA3133204A CA3133204A1 CA 3133204 A1 CA3133204 A1 CA 3133204A1 CA 3133204 A CA3133204 A CA 3133204A CA 3133204 A CA3133204 A CA 3133204A CA 3133204 A1 CA3133204 A1 CA 3133204A1
Authority
CA
Canada
Prior art keywords
smtp
group
formula
drug
compound represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3133204A
Other languages
English (en)
French (fr)
Inventor
Keita Shibata
Ryosuke SHINOUCHI
Terumasa Hashimoto
Koji NOBE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Showa University
Biogen MA Inc
Original Assignee
Showa University
TMS Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Showa University, TMS Co Ltd filed Critical Showa University
Publication of CA3133204A1 publication Critical patent/CA3133204A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3133204A 2019-03-12 2020-03-12 Drug and method for treating or preventing diabetes complications using same drug Pending CA3133204A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-044670 2019-03-12
JP2019044670 2019-03-12
PCT/JP2020/010967 WO2020184691A1 (ja) 2019-03-12 2020-03-12 薬剤及び該薬剤を用いて糖尿病合併症を治療又は予防する方法

Publications (1)

Publication Number Publication Date
CA3133204A1 true CA3133204A1 (en) 2020-09-17

Family

ID=72426033

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3133204A Pending CA3133204A1 (en) 2019-03-12 2020-03-12 Drug and method for treating or preventing diabetes complications using same drug

Country Status (15)

Country Link
US (1) US20220218664A1 (US06244707-20010612-C00010.png)
EP (1) EP3939659A4 (US06244707-20010612-C00010.png)
JP (1) JPWO2020184691A1 (US06244707-20010612-C00010.png)
KR (1) KR20220009371A (US06244707-20010612-C00010.png)
CN (1) CN114126711A (US06244707-20010612-C00010.png)
AU (1) AU2020238177A1 (US06244707-20010612-C00010.png)
BR (1) BR112021018084A8 (US06244707-20010612-C00010.png)
CA (1) CA3133204A1 (US06244707-20010612-C00010.png)
CL (1) CL2021002373A1 (US06244707-20010612-C00010.png)
EA (1) EA202192483A1 (US06244707-20010612-C00010.png)
IL (1) IL286289A (US06244707-20010612-C00010.png)
MX (1) MX2021011007A (US06244707-20010612-C00010.png)
PE (1) PE20220333A1 (US06244707-20010612-C00010.png)
SG (1) SG11202109982YA (US06244707-20010612-C00010.png)
WO (1) WO2020184691A1 (US06244707-20010612-C00010.png)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220040294A (ko) * 2020-09-23 2022-03-30 씨엔지바이오 주식회사 6-메톡시-2-펜에틸이소인돌린-1-온 유도체 및 이를 포함하는 신경질환의 치료용 조성물
TW202246289A (zh) * 2021-02-10 2022-12-01 大陸商上海森輝醫藥有限公司 一種ｓｍｔｐ－７衍生物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05176782A (ja) * 1992-01-08 1993-07-20 Taisho Pharmaceut Co Ltd Ｎｇｆ作用増強因子
JP4313049B2 (ja) 2003-01-23 2009-08-12 株式会社ティーティーシー 血管新生関連疾患の予防又は治療用医薬組成物
JP2004224737A (ja) 2003-01-23 2004-08-12 Ttc:Kk 新規トリプレニルフェノール化合物
US20090270476A1 (en) 2005-10-06 2009-10-29 Keiji Hasumi Pharmaceutical composition for treatment or prevention of nephritis and manufacturing method thereof
US8110596B2 (en) 2006-03-27 2012-02-07 Tokyo University Of Agriculture And Technology Tlo Co., Ltd. Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer
WO2010110026A1 (ja) * 2009-03-25 2010-09-30 国立大学法人東京農工大学 メタボリックシンドローム、肥満、高血糖症、高脂血症および／又は脂肪肝のための医薬組成物
US9078880B2 (en) * 2009-07-06 2015-07-14 National University Corporation Tokyo University Of Agriculture And Technology Cytoprotective agent
WO2011125930A1 (ja) * 2010-04-02 2011-10-13 日本製薬株式会社 炎症性腸疾患又は自己免疫性の末梢神経障害の予防又は治療剤
WO2012115209A1 (ja) * 2011-02-24 2012-08-30 国立大学法人東京農工大学 可溶性エポキシドハイドロラーゼ阻害剤
JP2019044670A (ja) 2017-08-31 2019-03-22 スズキ株式会社 内燃機関の排出ガス浄化システム

Also Published As

Publication number Publication date
EA202192483A1 (ru) 2021-12-24
US20220218664A1 (en) 2022-07-14
CN114126711A (zh) 2022-03-01
EP3939659A1 (en) 2022-01-19
PE20220333A1 (es) 2022-03-14
SG11202109982YA (en) 2021-10-28
AU2020238177A1 (en) 2021-11-04
BR112021018084A8 (pt) 2022-10-04
WO2020184691A1 (ja) 2020-09-17
CL2021002373A1 (es) 2022-06-17
IL286289A (en) 2021-10-31
MX2021011007A (es) 2022-03-11
EP3939659A4 (en) 2022-12-21
BR112021018084A2 (US06244707-20010612-C00010.png) 2021-12-21
KR20220009371A (ko) 2022-01-24
JPWO2020184691A1 (US06244707-20010612-C00010.png) 2020-09-17

Similar Documents

Publication Publication Date Title
EP2452679B1 (en) Triprenylphenolic cytoprotective agent
CA2336945C (en) Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
CA3133204A1 (en) Drug and method for treating or preventing diabetes complications using same drug
EA019935B1 (ru) Способы лечения алкогольной абстиненции
EP4087570A1 (en) Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
WO2017044551A1 (en) Ppar-alpha agonists for treating mitochondrial diseases
JP2024099786A (ja) 脳出血を治療又は予防するための薬剤及び該薬剤を用いて脳出血を治療又は予防する方法
JP2004525905A (ja) 双極性障害の予防もしくは治療における使用のためのカルバメート化合物
CA2320556A1 (en) N,n-dichlorinated omega amino acids and uses thereof
CA3097629A1 (en) Compositions and methods of use thereof to promote muscle growth and function
WO2022113371A1 (ja) 脳出血を治療又は予防するための薬剤及び該薬剤を用いて脳出血を治療又は予防する方法
EP3416955B1 (en) Use of stiripentol and their derivatives for decreasing urinary oxalate concentration in an individual
JP7356113B2 (ja) 薬剤及び該薬剤を用いて腎臓病を治療又は予防する方法
CA2464379A1 (en) Use of anti-glaucoma drugs to treat visual defects associated with the use of a gabaergic agent
MXPA99000255A (en) Treatment regimen for the administration of phenylacetilglutamine, phenylacetilisoglutamine and / or fen acetate
US20160022609A1 (en) Methods for treating chronic pain using a combination of bupropion ((±)-2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one) and phentermine (2-methyl-1-phenylpropan-2-amine)